Replication-deficient ebolavirus as a vaccine candidate.
about
Animal models for Ebola and Marburg virus infectionsCurrent ebola vaccinesEbola haemorrhagic feverEbola virus vaccines: an overview of current approachesThe organisation of Ebola virus reveals a capacity for extensive, modular polyploidyEbola and Marburg virus vaccines.A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus[Overview of the Ebola vaccines in pre-clinical and clinical development].Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 Å resolution.Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.A filtration based technique for simultaneous SEM and TEM sample preparation for the rapid detection of pathogens.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primatesEbolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.A mobile biosafety microanalysis system for infectious agentsKunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.Zinc binding activity of human metapneumovirus M2-1 protein is indispensable for viral replication and pathogenesis in vivo.Mouse STAT2 restricts early dengue virus replicationThe scanning electron microscope in microbiology and diagnosis of infectious disease.Progress in filovirus vaccine development: evaluating the potential for clinical use.The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.Phosphorylation of Human Metapneumovirus M2-1 Protein Upregulates Viral Replication and Pathogenesis.Reverse Genetics Approaches to Control Arenavirus.Reverse genetics systems as tools for the development of novel therapies against filoviruses.Ebola vaccines in clinical trial: The promising candidates.The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formationTherapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation.Lassa Virus Reverse Genetics.Updates on Treatment of Ebola Virus Disease.Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication.The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain.From bench to almost bedside: the long road to a licensed Ebola virus vaccine.Recent advances in vaccine development against Ebola threat as bioweapon.Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola VirusUse of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model
P2860
Q21131118-3F2F2B08-AE04-4C25-ACE2-D212FA433E94Q21534720-8F7483FE-DBD1-4FE9-812B-C72C79DE1C52Q24629338-BF21ADAA-39CB-47E9-AF18-58BE24B26167Q26999232-8199E1D0-A7DD-4065-80AC-04F713D14A73Q27310373-3B469239-3CB3-406F-A7DA-3F9D1B10AAE3Q30234637-5B92F0BE-591C-4395-8E34-FD4EBEF584B3Q30235073-C0D071EE-7A7A-4B1A-8847-01B569CEBFADQ30245207-2EF2383A-F9C6-4FD9-AEBB-8A67F77A64ECQ33551748-59E865CD-B38F-4795-9D80-0DFFA91DE308Q34204054-FA1D528F-869D-46AF-AD88-75340A5AA2E8Q34303578-A6C3A820-525D-4E32-ADD3-387E5D321AECQ34463780-8DFA5D86-545D-4094-9D9E-F267A46FBDB3Q34468847-A2A7770D-2371-4DAA-845F-A08BDC9F2746Q34540207-E24406CA-C296-4658-AB67-F2EAF661E563Q34761889-2D10DC7D-F54C-483F-8D3E-B0D82ADCFF5EQ34971349-C9AA4F8A-7C23-42A6-B110-2BB174F1D307Q35227372-5CB8FB7D-A32C-44B1-AE2A-6952488DFDEFQ35300048-7A30E0F5-6994-4C32-BC73-809E3015A5C7Q35760424-79F27743-7768-4F51-B0EC-66DAA1D656A9Q35846922-15DCA021-5294-4053-9965-8084709CDD46Q36025971-11407617-70C9-4370-A1CA-C5FF7B8A2C4DQ36100545-31FE185E-5550-4483-8B49-39690387B10FQ36978855-12CBFCD4-D79A-42F7-A347-98FBCB00CBC2Q37174437-EBD72A22-A49D-4EDB-940A-9E2F8F51E281Q37543755-D79FB9FD-D6D4-471D-B390-4B0BBC9ACD53Q38244444-C4DE3E1E-01E0-4EA6-A120-AAEA2EA4BDD4Q38808678-A453FEB5-5AFE-444E-87D7-B3FC2C882206Q39083915-05EE3E05-CE18-472B-93B3-DE558798F93FQ39225711-AA6C7B81-4349-483A-8AB7-F1A79C10E219Q39696796-A0CCE966-689A-46A0-97D4-72BCC10A3255Q40056797-53A10481-1E53-4F6E-B904-59B689ACFBEBQ40133255-48799D76-4A49-44CA-8B6B-E5E7083CF389Q40309150-B174CBE2-FCEC-42FE-8643-6060D3F1A62DQ40341178-17270063-4C14-4656-ADD2-ED8FA792729AQ44106264-5C7E749E-3AB8-4AC0-A8CF-0906FDF62081Q47559297-F38985EB-7CA5-402D-8130-C82F7E3049FDQ56535662-13DB7AEE-BCDF-446D-922F-BFDA99FDF4CEQ56576756-240A29ED-81CD-4B7E-B104-4017E8AEED43
P2860
Replication-deficient ebolavirus as a vaccine candidate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Replication-deficient ebolavirus as a vaccine candidate.
@en
Replication-deficient ebolavirus as a vaccine candidate.
@nl
type
label
Replication-deficient ebolavirus as a vaccine candidate.
@en
Replication-deficient ebolavirus as a vaccine candidate.
@nl
prefLabel
Replication-deficient ebolavirus as a vaccine candidate.
@en
Replication-deficient ebolavirus as a vaccine candidate.
@nl
P2093
P2860
P50
P356
P1433
P1476
Replication-deficient ebolavirus as a vaccine candidate.
@en
P2093
Gabriele Neumann
Peter Halfmann
Shinji Watanabe
Yasuko Hatta
P2860
P304
P356
10.1128/JVI.00074-09
P407
P577
2009-02-11T00:00:00Z